CASC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CASC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cascadian Therapeutics's interest expense for the three months ended in Dec. 2017 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2017 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cascadian Therapeutics's Operating Income for the three months ended in Dec. 2017 was $ -17.15 Mil. Cascadian Therapeutics's Interest Expense for the three months ended in Dec. 2017 was $ 0.00 Mil. Cascadian Therapeutics has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical data trend for Cascadian Therapeutics's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cascadian Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Cascadian Therapeutics Quarterly Data | ||||||||||||||||||||
Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | |
Interest Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cascadian Therapeutics (NAS:CASC) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Cascadian Therapeutics's Interest Expense for the three months ended in Dec. 2017 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2017 was $-17.15 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2017 was $0.00 Mil.
Cascadian Therapeutics's Interest Coverage for the quarter that ended in Dec. 2017 is calculated as
Cascadian Therapeutics had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Ted W Love | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Gwen A. Fyfe | director | C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301 |
Steven P James | director | C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
Julia Marie Eastland | officer: CFO & CBO | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Christopher S Henney | director | 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
Robert Azelby | director | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
Daniel K Spiegelman | director | MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003 |
Scott Dunseth Myers | director, officer: President and CEO | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Growth Equity Opportunities Iv, Llc | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Nea 15 Gp, Llc | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Nea Partners 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
New Enterprise Associates 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Jon Sakoda | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Florence Anthony A. Jr. | 10 percent owner | 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815 |
Peter W. Sonsini | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
From GuruFocus
By Holly LaFon Holly LaFon • 07-12-2016
By Kyle Ferguson Kyle Ferguson • 07-11-2016
By Henniker82 Henniker82 • 03-05-2013
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.